Servier
Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia
Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.
Backed by €19 million in EU funding, the initiative, called [email protected], will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.